Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies have?
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies has 29 citations in the OpenAlex counts ScholarIQ stores.
When was Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies published?
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies has 2024 year in the ScholarIQ index.
What is the open-access status of Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies?
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies has green oa status in the ScholarIQ index.
What is the DOI of Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies?
The DOI for Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies is on the source record.
What is the PMID of Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies?
The PMID for Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies is on the source record.
What is the OpenAlex record for Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies?
The OpenAlex for Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies is on the source record.